Research.Patient.info

Advance Radioactive-Iodine Refractory Differentiated Thyroid Cancer research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic exploratory (Phase II)
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
This study is testing a medicine called CABOMETYX for advanced thyroid cancer that hasn't responded to radioactive iodine treatment. Researchers are looking at blood samples to understand how the medicine works and if certain signs in the blood can predict who will benefit most.
Spain